U.S. markets closed
  • S&P Futures

    4,271.25
    -5.50 (-0.13%)
     
  • Dow Futures

    33,939.00
    -24.00 (-0.07%)
     
  • Nasdaq Futures

    13,463.75
    -29.50 (-0.22%)
     
  • Russell 2000 Futures

    1,989.70
    +0.60 (+0.03%)
     
  • Crude Oil

    87.99
    -0.12 (-0.14%)
     
  • Gold

    1,780.90
    +4.20 (+0.24%)
     
  • Silver

    19.75
    +0.02 (+0.10%)
     
  • EUR/USD

    1.0192
    +0.0011 (+0.11%)
     
  • 10-Yr Bond

    2.8930
    +0.0690 (+2.44%)
     
  • Vix

    19.90
    +0.21 (+1.07%)
     
  • GBP/USD

    1.2049
    -0.0003 (-0.02%)
     
  • USD/JPY

    134.8500
    -0.2400 (-0.18%)
     
  • BTC-USD

    23,464.46
    -530.96 (-2.21%)
     
  • CMC Crypto 200

    558.01
    -14.80 (-2.58%)
     
  • FTSE 100

    7,515.75
    -20.31 (-0.27%)
     
  • Nikkei 225

    28,956.00
    -266.77 (-0.91%)
     

Replimune to Present at Two Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:

BTIG Biotechnology Conference 2022
Date: Monday, August 8, 2022
Fireside Chat Time: 11:00 am ET

2022 Wedbush PacGrow Healthcare Virtual Conference
Date: Wednesday, August 10, 2022
Fireside Chat Time: 9:45 am ET

A live webcast and replay of the fireside chat at 2022 Wedbush PacGrow Healthcare Conference will also be available in the Investors section of Replimune’s website at www.replimune.com.

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com